146 related articles for article (PubMed ID: 10374333)
1. [Alterations of MDM2 and p53 genes in bone tumors].
Zhou X; Gao L; Zhe X
Zhonghua Bing Li Xue Za Zhi; 1997 Oct; 26(5):270-2. PubMed ID: 10374333
[TBL] [Abstract][Full Text] [Related]
2. [Detection of p53 and MDM2 gene expression in osteosarcoma with biotin-labelled in situ].
Wang X; Wang S; Feng C
Zhonghua Wai Ke Za Zhi; 1997 Mar; 35(3):178-80. PubMed ID: 10374529
[TBL] [Abstract][Full Text] [Related]
3. p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate.
Lonardo F; Ueda T; Huvos AG; Healey J; Ladanyi M
Cancer; 1997 Apr; 79(8):1541-7. PubMed ID: 9118036
[TBL] [Abstract][Full Text] [Related]
4. [Alterations of retinoblastoma gene and its protein expression in aggressive bone tumors].
Li Y; Qiu J
Zhonghua Bing Li Xue Za Zhi; 1997 Oct; 26(5):262-5. PubMed ID: 10374331
[TBL] [Abstract][Full Text] [Related]
5. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years.
Kawaguchi K; Oda Y; Sakamoto A; Saito T; Tamiya S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2002 Aug; 15(8):878-88. PubMed ID: 12181274
[TBL] [Abstract][Full Text] [Related]
6. Molecular analysis of p53, MDM2 and H-ras genes in low-grade central osteosarcoma.
Park HR; Jung WW; Bertoni F; Bacchini P; Park JH; Kim YW; Park YK
Pathol Res Pract; 2004; 200(6):439-45. PubMed ID: 15310147
[TBL] [Abstract][Full Text] [Related]
7. [TP53 gene aberrations in chondromatous neoplasms: correlation with immunohistochemical p53 accumulation and MDM2 expression].
Blasenbreu S; Baretton GB; Bender C; Haas CJ; Diebold J; Löhrs U
Verh Dtsch Ges Pathol; 1998; 82():284-9. PubMed ID: 10095448
[TBL] [Abstract][Full Text] [Related]
8. Alterations of the p53, Rb and MDM2 genes in osteosarcoma.
Miller CW; Aslo A; Won A; Tan M; Lampkin B; Koeffler HP
J Cancer Res Clin Oncol; 1996; 122(9):559-65. PubMed ID: 8781571
[TBL] [Abstract][Full Text] [Related]
9. Amplification of the CDK4 gene in sarcomas: tumor specificity and relationship with the RB gene mutation.
Kanoe H; Nakayama T; Murakami H; Hosaka T; Yamamoto H; Nakashima Y; Tsuboyama T; Nakamura T; Sasaki MS; Toguchida J
Anticancer Res; 1998; 18(4A):2317-21. PubMed ID: 9703873
[TBL] [Abstract][Full Text] [Related]
10. Expression of podoplanin in human bone and bone tumors: New marker of osteogenic and chondrogenic bone tumors.
Ariizumi T; Ogose A; Kawashima H; Hotta T; Li G; Xu Y; Umezu H; Sugai M; Endo N
Pathol Int; 2010 Mar; 60(3):193-202. PubMed ID: 20403045
[TBL] [Abstract][Full Text] [Related]
11. Status of the p53, Rb and MDM2 genes in canine osteosarcoma.
Mendoza S; Konishi T; Dernell WS; Withrow SJ; Miller CW
Anticancer Res; 1998; 18(6A):4449-53. PubMed ID: 9891508
[TBL] [Abstract][Full Text] [Related]
12. Expression of c-met proto-oncogene product (c-MET) in benign and malignant bone tumors.
Naka T; Iwamoto Y; Shinohara N; Ushijima M; Chuman H; Tsuneyoshi M
Mod Pathol; 1997 Aug; 10(8):832-8. PubMed ID: 9267827
[TBL] [Abstract][Full Text] [Related]
13. [Genetic instability in osteoblastic tumors of the skeletal system].
Roessner A; Radig K; Schneider-Stock R; Mittler U; Neumann HW
Verh Dtsch Ges Pathol; 1998; 82():133-43. PubMed ID: 10095425
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic implications of MDM2, p53 and K-ras gene alterations in osteosarcomas: MDM2 amplification and p53 mutations found in progressive tumors.
Yokoyama R; Schneider-Stock R; Radig K; Wex T; Roessner A
Pathol Res Pract; 1998; 194(9):615-21. PubMed ID: 9793960
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the 12q15 MDM2 and 12q13-14 CDK4 amplicons and clinical correlations in osteosarcoma.
Mejia-Guerrero S; Quejada M; Gokgoz N; Gill M; Parkes RK; Wunder JS; Andrulis IL
Genes Chromosomes Cancer; 2010 Jun; 49(6):518-25. PubMed ID: 20196171
[TBL] [Abstract][Full Text] [Related]
16. Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer.
Lenos K; Grawenda AM; Lodder K; Kuijjer ML; Teunisse AF; Repapi E; Grochola LF; Bartel F; Hogendoorn PC; Wuerl P; Taubert H; Cleton-Jansen AM; Bond GL; Jochemsen AG
Cancer Res; 2012 Aug; 72(16):4074-84. PubMed ID: 22700878
[TBL] [Abstract][Full Text] [Related]
17. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer.
Osman I; Scher HI; Zhang ZF; Pellicer I; Hamza R; Eissa S; Khaled H; Cordon-Cardo C
Clin Cancer Res; 1997 Apr; 3(4):531-6. PubMed ID: 9815716
[TBL] [Abstract][Full Text] [Related]
18. MDM2 gene amplification in bone and soft-tissue tumors: association with tumor progression in differentiated adipose-tissue tumors.
Nakayama T; Toguchida J; Wadayama B; Kanoe H; Kotoura Y; Sasaki MS
Int J Cancer; 1995 Oct; 64(5):342-6. PubMed ID: 7591308
[TBL] [Abstract][Full Text] [Related]
19. p53 mutation and absence of mdm2 amplification and Ki-ras mutation in 4-hydroxyamino quinoline 1-oxide induced transplantable osteosarcomas in rats.
Kido A; Tsujiuchi T; Tsutsumi M; Takahama M; Okajima E; Kobitsu K; Miyauchi Y; Mii Y; Tamai S; Konishi Y
Cancer Lett; 1997 Jan; 112(1):5-10. PubMed ID: 9029163
[TBL] [Abstract][Full Text] [Related]
20. p53 and MDM2 in the development and progression of bladder cancer.
Schmitz-Dräger BJ; Kushima M; Goebell P; Jax TW; Gerharz CD; Bültel H; Schulz WA; Ebert T; Ackermann R
Eur Urol; 1997; 32(4):487-93. PubMed ID: 9412812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
